Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-02

AUTHORS

Marc Evans, Plamen Kozlovski, Päivi M. Paldánius, James E. Foley, Vaishali Bhosekar, Carmen Serban, Angelo Avogaro

ABSTRACT

INTRODUCTION: In a meta-analysis, we observed a significant 37% relative risk reduction in prospectively adjudicated major adverse cardiac events [MACEs, comprising of non-fatal myocardial infarction, non-fatal stroke, cardiovascular (CV) death] with vildagliptin vs. comparators in younger (< 65 years) patients with type 2 diabetes mellitus (T2DM), while the risk was similar in older patients (≥ 65 years). We carried out an exploratory analysis to identify the patient characteristics and on-treatment effects that may have contributed to the different outcomes in the two age groups. METHODS: On-treatment differences (vildagliptin vs. comparators) for the change from baseline in CV risk factors were analyzed using an analysis of covariance model with the baseline value for each variable of interest, treatment and study as covariates. Additional adjustments for background antihypertensive and statin use were performed when analyzing changes in blood pressure and lipids, respectively. Baseline characteristics and patient demographics were analyzed using descriptive statistics. RESULTS: Patients aged < 65 years had shorter diabetes duration (4.4 vs. 8.2 years) and slightly higher glycated hemoglobin (HbA1c) at baseline (8.3% vs. 8.0%) than patients aged ≥ 65 years. More patients in the ≥ 65 year age group had hypertension (73.1% vs. 51.3%), dyslipidemia (53.3% vs. 43.9%) and a history of CV events (32.2% vs. 12.9%). There were small, but statistically significant differences in the change in HbA1c and total cholesterol in favor of vildagliptin relative to comparators, which were similar in both age groups. Significant differences were observed in the reduction in systolic blood pressure (SBP) (- 0.52 mmHg; 95% CI - 0.97, - 0.07; p = 0.023), low-density lipoprotein (LDL cholesterol) (- 0.12 mmol/l; 95% CI - 0.19, - 0.04; p = 0.002) and weight (- 0.48 kg; 95% CI - 0.95, - 0.01; p < 0.047) in patients < 65 years, but not in patients ≥ 65 years. The incidence of hypoglycemic events was lower in patients treated with vildagliptin [2.1 and 3.5 per 100 subject years exposure (SYEs) in < 65 and ≥ 65 years, respectively] than with comparators (5.8 and 7.5 per 100 SYEs, respectively). CONCLUSION: Based on our findings, it can be hypothesized that the positive effects of vildagliptin on SBP, LDL cholesterol, hypoglycemia and weight observed in younger, but not in older patients could be associated with the lower risk of MACE in younger patients with T2DM. FUNDING: Novartis. More... »

PAGES

27-36

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-017-0329-5

DOI

http://dx.doi.org/10.1007/s13300-017-0329-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1092656569

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29134608


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Cardiff and Vale University Health Board", 
          "id": "https://www.grid.ac/institutes/grid.273109.e", 
          "name": [
            "Diabetes Resource Centre, University Hospital Llandough, Cardiff, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Evans", 
        "givenName": "Marc", 
        "id": "sg:person.01167546340.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167546340.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kozlovski", 
        "givenName": "Plamen", 
        "id": "sg:person.0632706070.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632706070.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pald\u00e1nius", 
        "givenName": "P\u00e4ivi M.", 
        "id": "sg:person.01114726145.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114726145.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Foley", 
        "givenName": "James E.", 
        "id": "sg:person.01371275503.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371275503.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (India)", 
          "id": "https://www.grid.ac/institutes/grid.464975.d", 
          "name": [
            "Novartis Healthcare Private Limited, Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bhosekar", 
        "givenName": "Vaishali", 
        "id": "sg:person.013137310337.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013137310337.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Serban", 
        "givenName": "Carmen", 
        "id": "sg:person.010174571773.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010174571773.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Padua", 
          "id": "https://www.grid.ac/institutes/grid.5608.b", 
          "name": [
            "Department of Medicine, University of Padova, Padua, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Avogaro", 
        "givenName": "Angelo", 
        "id": "sg:person.01322532335.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322532335.70"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejmoa1307684", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003605360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1008862", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008774917"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1603827", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010225149"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/hrt.2004.035766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012243700"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1501352", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014732526"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(98)07037-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015697368"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.numecd.2012.09.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017548127"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1305889", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018262898"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa021778", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018344641"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0706245", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018706980"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc14-2441", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021071301"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/vhrm.s112148", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026345937"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2014.1873", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027763582"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1504720", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027808643"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.12821", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028602017"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.12548", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032866152"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1463-1326.2010.01215.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033808144"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1463-1326.2010.01215.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033808144"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0806470", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034293538"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/vhrm.s8216", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036004689"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1479164115570301", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036826725"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1479164115570301", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036826725"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dme.12508", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048147313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(10)60484-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050271356"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/01926230701226575", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058308389"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/01926230701226575", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058308389"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc16-0303", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070730227"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc16-0303", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070730227"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4239/wjd.v5.i4.444", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072397487"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.12906", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083820478"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1611925", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085993372"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.17925/ee.2017.13.02.62", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091697842"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-02", 
    "datePublishedReg": "2018-02-01", 
    "description": "INTRODUCTION: In a meta-analysis, we observed a significant 37% relative risk reduction in prospectively adjudicated major adverse cardiac events [MACEs, comprising of non-fatal myocardial infarction, non-fatal stroke, cardiovascular (CV) death] with vildagliptin vs. comparators in younger (<\u00a065\u00a0years) patients with type 2 diabetes mellitus (T2DM), while the risk was similar in older patients (\u2265\u00a065\u00a0years). We carried out an exploratory analysis to identify the patient characteristics and on-treatment effects that may have contributed to the different outcomes in the two age groups.\nMETHODS: On-treatment differences (vildagliptin vs. comparators) for the change from baseline in CV risk factors were analyzed using an analysis of covariance model with the baseline value for each variable of interest, treatment and study as covariates. Additional adjustments for background antihypertensive and statin use were performed when analyzing changes in blood pressure and lipids, respectively. Baseline characteristics and patient demographics were analyzed using descriptive statistics.\nRESULTS: Patients aged\u00a0<\u00a065\u00a0years had shorter diabetes duration (4.4 vs. 8.2\u00a0years) and slightly higher glycated hemoglobin (HbA1c) at baseline (8.3% vs. 8.0%) than patients aged\u00a0\u2265\u00a065\u00a0years. More patients in the \u00a0\u2265\u00a065\u00a0year age group had hypertension (73.1% vs. 51.3%), dyslipidemia (53.3% vs. 43.9%) and a history of CV events (32.2% vs. 12.9%). There were small, but statistically significant differences in the change in HbA1c and total cholesterol in favor of vildagliptin relative to comparators, which were similar in both age groups. Significant differences were observed in the reduction in systolic blood pressure (SBP) (-\u00a00.52\u00a0mmHg; 95% CI -\u00a00.97, -\u00a00.07; p\u00a0=\u00a00.023), low-density lipoprotein (LDL cholesterol) (-\u00a00.12\u00a0mmol/l; 95% CI -\u00a00.19, -\u00a00.04; p\u00a0=\u00a00.002) and weight (-\u00a00.48\u00a0kg; 95% CI -\u00a00.95, -\u00a00.01; p\u00a0<\u00a00.047) in patients\u00a0<\u00a065\u00a0years, but not in patients\u00a0\u2265\u00a065\u00a0years. The incidence of hypoglycemic events was lower in patients treated with vildagliptin [2.1 and 3.5 per 100 subject years exposure (SYEs) in\u00a0<\u00a065 and\u00a0\u2265\u00a065\u00a0years, respectively] than with comparators (5.8 and 7.5 per 100 SYEs, respectively).\nCONCLUSION: Based on our findings, it can be hypothesized that the positive effects of vildagliptin on SBP, LDL cholesterol, hypoglycemia and weight observed in younger, but not in older patients could be associated with the lower risk of MACE in younger patients with T2DM.\nFUNDING: Novartis.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s13300-017-0329-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "name": "Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus", 
    "pagination": "27-36", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "bb1de95ebf2aab3487d63e715fc4ef5c14cbf95bdcd63dfdcfb37a315e17b14b"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29134608"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101539025"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-017-0329-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1092656569"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-017-0329-5", 
      "https://app.dimensions.ai/details/publication/pub.1092656569"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T13:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8659_00000493.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s13300-017-0329-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-017-0329-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-017-0329-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-017-0329-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-017-0329-5'


 

This table displays all metadata directly associated to this object as RDF triples.

207 TRIPLES      21 PREDICATES      57 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-017-0329-5 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N56ae66f7fe584ce2a269c84da2de9242
4 schema:citation https://doi.org/10.1001/jama.2014.1873
5 https://doi.org/10.1016/j.numecd.2012.09.003
6 https://doi.org/10.1016/s0140-6736(10)60484-9
7 https://doi.org/10.1016/s0140-6736(98)07037-8
8 https://doi.org/10.1056/nejmoa021778
9 https://doi.org/10.1056/nejmoa0706245
10 https://doi.org/10.1056/nejmoa0806470
11 https://doi.org/10.1056/nejmoa1008862
12 https://doi.org/10.1056/nejmoa1305889
13 https://doi.org/10.1056/nejmoa1307684
14 https://doi.org/10.1056/nejmoa1501352
15 https://doi.org/10.1056/nejmoa1504720
16 https://doi.org/10.1056/nejmoa1603827
17 https://doi.org/10.1056/nejmoa1611925
18 https://doi.org/10.1080/01926230701226575
19 https://doi.org/10.1111/dme.12508
20 https://doi.org/10.1111/dom.12548
21 https://doi.org/10.1111/dom.12821
22 https://doi.org/10.1111/dom.12906
23 https://doi.org/10.1111/j.1463-1326.2010.01215.x
24 https://doi.org/10.1136/hrt.2004.035766
25 https://doi.org/10.1177/1479164115570301
26 https://doi.org/10.17925/ee.2017.13.02.62
27 https://doi.org/10.2147/vhrm.s112148
28 https://doi.org/10.2147/vhrm.s8216
29 https://doi.org/10.2337/dc14-2441
30 https://doi.org/10.2337/dc16-0303
31 https://doi.org/10.4239/wjd.v5.i4.444
32 schema:datePublished 2018-02
33 schema:datePublishedReg 2018-02-01
34 schema:description INTRODUCTION: In a meta-analysis, we observed a significant 37% relative risk reduction in prospectively adjudicated major adverse cardiac events [MACEs, comprising of non-fatal myocardial infarction, non-fatal stroke, cardiovascular (CV) death] with vildagliptin vs. comparators in younger (< 65 years) patients with type 2 diabetes mellitus (T2DM), while the risk was similar in older patients (≥ 65 years). We carried out an exploratory analysis to identify the patient characteristics and on-treatment effects that may have contributed to the different outcomes in the two age groups. METHODS: On-treatment differences (vildagliptin vs. comparators) for the change from baseline in CV risk factors were analyzed using an analysis of covariance model with the baseline value for each variable of interest, treatment and study as covariates. Additional adjustments for background antihypertensive and statin use were performed when analyzing changes in blood pressure and lipids, respectively. Baseline characteristics and patient demographics were analyzed using descriptive statistics. RESULTS: Patients aged < 65 years had shorter diabetes duration (4.4 vs. 8.2 years) and slightly higher glycated hemoglobin (HbA1c) at baseline (8.3% vs. 8.0%) than patients aged ≥ 65 years. More patients in the  ≥ 65 year age group had hypertension (73.1% vs. 51.3%), dyslipidemia (53.3% vs. 43.9%) and a history of CV events (32.2% vs. 12.9%). There were small, but statistically significant differences in the change in HbA1c and total cholesterol in favor of vildagliptin relative to comparators, which were similar in both age groups. Significant differences were observed in the reduction in systolic blood pressure (SBP) (- 0.52 mmHg; 95% CI - 0.97, - 0.07; p = 0.023), low-density lipoprotein (LDL cholesterol) (- 0.12 mmol/l; 95% CI - 0.19, - 0.04; p = 0.002) and weight (- 0.48 kg; 95% CI - 0.95, - 0.01; p < 0.047) in patients < 65 years, but not in patients ≥ 65 years. The incidence of hypoglycemic events was lower in patients treated with vildagliptin [2.1 and 3.5 per 100 subject years exposure (SYEs) in < 65 and ≥ 65 years, respectively] than with comparators (5.8 and 7.5 per 100 SYEs, respectively). CONCLUSION: Based on our findings, it can be hypothesized that the positive effects of vildagliptin on SBP, LDL cholesterol, hypoglycemia and weight observed in younger, but not in older patients could be associated with the lower risk of MACE in younger patients with T2DM. FUNDING: Novartis.
35 schema:genre research_article
36 schema:inLanguage en
37 schema:isAccessibleForFree true
38 schema:isPartOf N3ed114082e7245d293687922f3be5fc9
39 N80c13fd121fa4c4893edff0ba2e13af8
40 sg:journal.1044057
41 schema:name Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus
42 schema:pagination 27-36
43 schema:productId N2239d496693241d3a8d97159a081abd6
44 N48af0139f96c408d9461402f9e31e264
45 N88cab2f563134b21bf0a88acdc5480e4
46 N9def5489683f4959a085eb6a7aa71bb6
47 Nab8a67c5ec464ab4a19994e8376beb11
48 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092656569
49 https://doi.org/10.1007/s13300-017-0329-5
50 schema:sdDatePublished 2019-04-10T13:10
51 schema:sdLicense https://scigraph.springernature.com/explorer/license/
52 schema:sdPublisher N3b43e9a9c7474fb9bcfbc5ec0aaf3107
53 schema:url http://link.springer.com/10.1007/s13300-017-0329-5
54 sgo:license sg:explorer/license/
55 sgo:sdDataset articles
56 rdf:type schema:ScholarlyArticle
57 N18a7cb51f8fb41bd90ec0bd463116955 rdf:first sg:person.01322532335.70
58 rdf:rest rdf:nil
59 N2239d496693241d3a8d97159a081abd6 schema:name doi
60 schema:value 10.1007/s13300-017-0329-5
61 rdf:type schema:PropertyValue
62 N3b43e9a9c7474fb9bcfbc5ec0aaf3107 schema:name Springer Nature - SN SciGraph project
63 rdf:type schema:Organization
64 N3ed114082e7245d293687922f3be5fc9 schema:volumeNumber 9
65 rdf:type schema:PublicationVolume
66 N4899fe8f0cee4ae68be3d3913aac46ff rdf:first sg:person.013137310337.01
67 rdf:rest Nadc2c1b8f7ea465e8e06e2548cf67c93
68 N48af0139f96c408d9461402f9e31e264 schema:name readcube_id
69 schema:value bb1de95ebf2aab3487d63e715fc4ef5c14cbf95bdcd63dfdcfb37a315e17b14b
70 rdf:type schema:PropertyValue
71 N56ae66f7fe584ce2a269c84da2de9242 rdf:first sg:person.01167546340.80
72 rdf:rest Nb94578812ab043759f8d5436a57ca32f
73 N62aa9399c9164612b47680329011038d rdf:first sg:person.01371275503.30
74 rdf:rest N4899fe8f0cee4ae68be3d3913aac46ff
75 N80c13fd121fa4c4893edff0ba2e13af8 schema:issueNumber 1
76 rdf:type schema:PublicationIssue
77 N88cab2f563134b21bf0a88acdc5480e4 schema:name pubmed_id
78 schema:value 29134608
79 rdf:type schema:PropertyValue
80 N9def5489683f4959a085eb6a7aa71bb6 schema:name nlm_unique_id
81 schema:value 101539025
82 rdf:type schema:PropertyValue
83 Nab8a67c5ec464ab4a19994e8376beb11 schema:name dimensions_id
84 schema:value pub.1092656569
85 rdf:type schema:PropertyValue
86 Nadc2c1b8f7ea465e8e06e2548cf67c93 rdf:first sg:person.010174571773.88
87 rdf:rest N18a7cb51f8fb41bd90ec0bd463116955
88 Nb94578812ab043759f8d5436a57ca32f rdf:first sg:person.0632706070.29
89 rdf:rest Ne4c2323adf2844d8a01e06abb6e3c52e
90 Ne4c2323adf2844d8a01e06abb6e3c52e rdf:first sg:person.01114726145.93
91 rdf:rest N62aa9399c9164612b47680329011038d
92 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
93 schema:name Medical and Health Sciences
94 rdf:type schema:DefinedTerm
95 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
96 schema:name Clinical Sciences
97 rdf:type schema:DefinedTerm
98 sg:journal.1044057 schema:issn 1869-6953
99 1869-6961
100 schema:name Diabetes Therapy
101 rdf:type schema:Periodical
102 sg:person.010174571773.88 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
103 schema:familyName Serban
104 schema:givenName Carmen
105 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010174571773.88
106 rdf:type schema:Person
107 sg:person.01114726145.93 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
108 schema:familyName Paldánius
109 schema:givenName Päivi M.
110 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114726145.93
111 rdf:type schema:Person
112 sg:person.01167546340.80 schema:affiliation https://www.grid.ac/institutes/grid.273109.e
113 schema:familyName Evans
114 schema:givenName Marc
115 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167546340.80
116 rdf:type schema:Person
117 sg:person.013137310337.01 schema:affiliation https://www.grid.ac/institutes/grid.464975.d
118 schema:familyName Bhosekar
119 schema:givenName Vaishali
120 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013137310337.01
121 rdf:type schema:Person
122 sg:person.01322532335.70 schema:affiliation https://www.grid.ac/institutes/grid.5608.b
123 schema:familyName Avogaro
124 schema:givenName Angelo
125 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322532335.70
126 rdf:type schema:Person
127 sg:person.01371275503.30 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
128 schema:familyName Foley
129 schema:givenName James E.
130 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371275503.30
131 rdf:type schema:Person
132 sg:person.0632706070.29 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
133 schema:familyName Kozlovski
134 schema:givenName Plamen
135 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632706070.29
136 rdf:type schema:Person
137 https://doi.org/10.1001/jama.2014.1873 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027763582
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1016/j.numecd.2012.09.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017548127
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1016/s0140-6736(10)60484-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050271356
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1016/s0140-6736(98)07037-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015697368
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1056/nejmoa021778 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018344641
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1056/nejmoa0706245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018706980
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1056/nejmoa0806470 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034293538
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1056/nejmoa1008862 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008774917
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1056/nejmoa1305889 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018262898
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1056/nejmoa1307684 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003605360
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1056/nejmoa1501352 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014732526
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1056/nejmoa1504720 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027808643
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1056/nejmoa1603827 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010225149
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1056/nejmoa1611925 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085993372
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1080/01926230701226575 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058308389
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1111/dme.12508 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048147313
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1111/dom.12548 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032866152
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1111/dom.12821 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028602017
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1111/dom.12906 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083820478
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1111/j.1463-1326.2010.01215.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1033808144
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1136/hrt.2004.035766 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012243700
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1177/1479164115570301 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036826725
180 rdf:type schema:CreativeWork
181 https://doi.org/10.17925/ee.2017.13.02.62 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091697842
182 rdf:type schema:CreativeWork
183 https://doi.org/10.2147/vhrm.s112148 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026345937
184 rdf:type schema:CreativeWork
185 https://doi.org/10.2147/vhrm.s8216 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036004689
186 rdf:type schema:CreativeWork
187 https://doi.org/10.2337/dc14-2441 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021071301
188 rdf:type schema:CreativeWork
189 https://doi.org/10.2337/dc16-0303 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070730227
190 rdf:type schema:CreativeWork
191 https://doi.org/10.4239/wjd.v5.i4.444 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072397487
192 rdf:type schema:CreativeWork
193 https://www.grid.ac/institutes/grid.273109.e schema:alternateName Cardiff and Vale University Health Board
194 schema:name Diabetes Resource Centre, University Hospital Llandough, Cardiff, UK
195 rdf:type schema:Organization
196 https://www.grid.ac/institutes/grid.418424.f schema:alternateName Novartis (United States)
197 schema:name Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
198 rdf:type schema:Organization
199 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
200 schema:name Novartis Pharma AG, Basel, Switzerland
201 rdf:type schema:Organization
202 https://www.grid.ac/institutes/grid.464975.d schema:alternateName Novartis (India)
203 schema:name Novartis Healthcare Private Limited, Hyderabad, India
204 rdf:type schema:Organization
205 https://www.grid.ac/institutes/grid.5608.b schema:alternateName University of Padua
206 schema:name Department of Medicine, University of Padova, Padua, Italy
207 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...